PCVX VAXCYTE INC revenue, earnings and financials
For the quarter ended June 30, 2026, VAXCYTE INC reported revenue of n/a, net income of −$284M and diluted EPS of −$1.97; for the fiscal year ended December 2025 revenue was n/a.
PCVX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$924M, net income −$767K (margin n/a), EPS −$5.63
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$570M, net income −$464K (margin n/a), EPS −$3.80
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$468M, net income −$402K (margin n/a), EPS −$4.14
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$232M, net income −$223K (margin n/a), EPS −$3.44
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$104M, net income −$100K (margin n/a), EPS −$1.93
PCVX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$284M, EPS −$1.97
- Quarter ended Mar 31, 2026: revenue n/a, net income −$321M, EPS −$2.30
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $519M, EPS −$1.81
- Quarter ended Sep 30, 2025: revenue n/a, net income −$213M, EPS −$1.56
- Quarter ended Jun 30, 2025: revenue n/a, net income −$167M, EPS −$1.22
- Quarter ended Mar 31, 2025: revenue n/a, net income −$141M, EPS −$1.04
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $326M, EPS −$1.02
- Quarter ended Sep 30, 2024: revenue n/a, net income −$103M, EPS −$0.83
- Quarter ended Jun 30, 2024: revenue n/a, net income −$129M, EPS −$1.10
- Quarter ended Mar 31, 2024: revenue n/a, net income −$95.0M, EPS −$0.85
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $221M, EPS −$1.83
- Quarter ended Sep 30, 2023: revenue n/a, net income −$92.7M, EPS −$0.91
- Quarter ended Jun 30, 2023: revenue n/a, net income −$68.3M, EPS −$0.70
- Quarter ended Mar 31, 2023: revenue n/a, net income −$60.5M, EPS −$0.70
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $145M, EPS −$1.03
- Quarter ended Sep 30, 2022: revenue n/a, net income −$57.9M, EPS −$0.93
- Quarter ended Jun 30, 2022: revenue n/a, net income −$48.5M, EPS −$0.80
- Quarter ended Mar 31, 2022: revenue n/a, net income −$39.0M, EPS −$0.68
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $71.4M, EPS −$0.55
- Quarter ended Sep 30, 2021: revenue n/a, net income −$26.6M, EPS −$0.51
PCVX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$656M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$453M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$297M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$171M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$121M, share buybacks n/a, dividends $0.00 per share
PCVX balance sheet
- Jun 30, 2026: cash $183M, total assets $3.14B, total liabilities $380M, shareholders' equity $2.76B
- Mar 31, 2026: cash $261M, total assets $3.35B, total liabilities $352M, shareholders' equity $3.00B
- Dec 31, 2025: cash $174M, total assets $3.00B, total liabilities $317M, shareholders' equity $2.69B
- Sep 30, 2025: cash $281M, total assets $3.17B, total liabilities $279M, shareholders' equity $2.89B
- Jun 30, 2025: cash $307M, total assets $3.31B, total liabilities $234M, shareholders' equity $3.07B
- Mar 31, 2025: cash $347M, total assets $3.38B, total liabilities $178M, shareholders' equity $3.20B
- Dec 31, 2024: cash $388M, total assets $3.51B, total liabilities $205M, shareholders' equity $3.31B
- Sep 30, 2024: cash $1.05B, total assets $3.56B, total liabilities $142M, shareholders' equity $3.42B
Is PCVX profitable?
No. VAXCYTE INC lost $298M over the last four quarters.
What is PCVX's EPS?
Diluted earnings per share over the last four quarters were −$7.64; −$1.97 in the latest quarter.